<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02917265</url>
  </required_header>
  <id_info>
    <org_study_id>H15-141</org_study_id>
    <nct_id>NCT02917265</nct_id>
  </id_info>
  <brief_title>Transcutaneous Vagus Nerve Stimulation for the Treatment of Lupus</brief_title>
  <acronym>TRUST</acronym>
  <official_title>Transcutaneous Vagus Nerve Stimulation for the Treatment of Systemic Lupus Erythematosus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aikaterini Thanou</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Oklahoma Medical Research Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Oklahoma</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Aikaterini Thanou</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a 3-month double blinded randomized controlled study of transcutaneous electrical
      vagus nerve stimulation (tVNS) compared to a sham stimulation for the treatment of patients
      with active systemic lupus erythematosus (SLE).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with SLE and active, non-organ-threatening disease are eligible to participate in
      this prospective randomized double blind trial of active or sham transcutaneous electrical
      vagus nerve stimulation (tVNS). Active tNVS is performed by the use of a transcutaneous
      electrical nerve stimulation (TENS) device with electrodes attached to an area of the
      external ear innervated by the auricular branch of the vagus nerve. The same protocol is
      followed in the sham tVNS arm, but the pads are placed on an area of the external ear that is
      devoid of vagus innervation.TENS is applied for 60 to 120 minutes daily as tolerated and
      participants keep a detailed log of their daily TENS sessions. Patients return to clinic at
      weeks 4, 8 and 12 for study related assessments.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    poor recruitment
  </why_stopped>
  <start_date type="Actual">November 2015</start_date>
  <completion_date type="Actual">November 2018</completion_date>
  <primary_completion_date type="Actual">May 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants on Active vs Sham tVNS With Improvement in SLE Disease Activity by the BILAG-based Combined Lupus Assessment (BICLA)</measure>
    <time_frame>12 weeks</time_frame>
    <description>Achieving a BICLA response requires to meet all of the following parameters:
All British Isles Lupus Assessment Group (BILAG) A scores improving to B/C/D and all BILAG level B scores improving to C/D
No single new BILAG A &amp; not &gt;1 new BILAG B scores, no worsening of the baseline Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) total score AND no worsening in the Physician Global Assessment (PGA) (&lt;10% worsening from baseline)
No initiation of non-protocol treatments or premature study discontinuation
The range of values for the above instruments are listed below, with higher scores indicating more active disease:
BILAG: 0 to 96 SLEDAI: 0 to 105 PGA: 0-3</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants on Active vs Sham tVNS With Improvement in SLE Disease Activity by the Systemic Lupus Erythematosus Responder Index (SRI-4)</measure>
    <time_frame>12 weeks</time_frame>
    <description>SRI requires meeting all of the following parameters:
≥4-point reduction from baseline in the Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) score
No single new British Isles Lupus Assessment Group (BILAG) A score &amp; not &gt;1 new BILAG B scores AND no worsening in the Physician Global Assessment (PGA) (&lt;10% worsening from baseline)
No initiation of non-protocol treatments or premature study discontinuation
The range of values for the above instruments are listed below, with higher scores indicating more active disease:
BILAG: 0 to 96 SLEDAI: 0 to 108 PGA: 0-3</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants on Active vs Sham tVNS With Improvement in Heart Rate Variability (HRV)</measure>
    <time_frame>12 weeks</time_frame>
    <description>HRV is measured by time domain (RMSSD and pNN50) and frequency domain [high frequency (HF), low to high frequency (LF/HF) ratio] parameters.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Percentage of Participants on Active vs Sham tVNS That Experience an SLE Flare by SELENA SLEDAI Flare Index</measure>
    <time_frame>12 weeks</time_frame>
    <description>The SELENA SLEDAI flare index captures flares in the preceding 30 days by a combination of clinical descriptors and medications rules.</description>
  </other_outcome>
  <other_outcome>
    <measure>Percentage of Participants on Active vs Sham tVNS With Improvement in Quality of Life Measured by the Lupus QoL</measure>
    <time_frame>12 weeks</time_frame>
    <description>The Lupus QoL is a patient reported outcome developed for measurement of quality of life of patients with SLE in clinical research</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">7</enrollment>
  <condition>Systemic Lupus Erythematosus</condition>
  <arm_group>
    <arm_group_label>TENS for vagus stimulation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A transcutaneous electrical nerve stimulation (TENS) unit is applied to an area of the external ear that is innervated by the auricular branch of the vagus nerve.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TENS for sham stimulation</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>A TENS unit is applied to an area of the external ear that is devoid of vagus innervation.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>TENS for vagus stimulation</intervention_name>
    <description>TENS electrodes are applied on an area of the external ear innervated by the auricular branch of the vagus nerve.</description>
    <arm_group_label>TENS for vagus stimulation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>TENS for sham stimulation</intervention_name>
    <description>TENS electrodes are applied on an area of the external ear devoid of vagus innervation.</description>
    <arm_group_label>TENS for sham stimulation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients with SLE age 18-70 meeting the American College of Rheumatology
             Classification Criteria. Patients need to meet a minimum of 4 out of 11 criteria
             simultaneously or serially on two separate occasions.

          2. Positive antinuclear antibody or anti-dsDNA within one year of screening

          3. Non-serological SLEDAI ≥4 or ≥1 BILAG B or A and presence of inflammatory arthritis
             (defined by at least 3 swollen and 3 tender joints) at screening

          4. Patients may receive on one or more of the following immune suppressive therapies:
             hydroxychloroquine, quinacrine, methotrexate, azathioprine, mycophenolate mofetil,
             tacrolimus, sirolimus, belimumab, abatacept. Immune suppressive medications should
             have been administered at stable doses for ≥30 days prior to baseline. Patients may
             also be on prednisone up to 10mg daily or equivalent steroid treatment at the baseline
             visit.

        Exclusion Criteria:

          1. Acute lupus nephritis defined as class II,III, IV or V nephritis diagnosed within 6
             months or prot/creat &gt; 1.5 gm/gm due to active lupus or in process of receiving
             induction therapy for nephritis

          2. Active CNS lupus affecting mental status

          3. Any other organ threatening or life threatening manifestation of SLE as well as those,
             who, in the opinion of the investigator, have severe multi-organ or refractory lupus

          4. Rituximab treatment within 6 months prior to screening and/or without return of B
             cells to baseline levels

          5. Treatment with cyclophosphamide within a month prior to screening

          6. Treatment with any investigational drug within 3 months or 5 half-lives whichever is
             longer

          7. Recurrent vaso-vagal syncopal episodes

          8. Unilateral or bilateral vagotomy

          9. Presence of any evidence of vagus nerve pathology or injury

         10. Heart failure (NYHA class III or IV)

         11. Known atherosclerotic disease, including severe carotid artery disease, uncontrolled
             hypertension, uncontrolled diabetes, and history of myocardial infarction (MI),
             cardiomyopathy or stroke within the past year. Clinically stable patients with
             coronary artery disease, but no recent MI (within the past year) and no current
             symptoms of angina are not however excluded.

         12. Valvular and other structural heart disease that is evident by transthoracic
             echocardiogram and is associated with heart failure (NYHA class III or IV)

         13. Prolonged QT interval or abnormal baseline ECG - sick sinus syndrome, Mobitz type 2
             second or third degree heart block, atrial fibrillation, atrial flutter, recent
             history of ventricular tachycardia or ventricular fibrillation or clinically
             significant premature ventricular contraction

         14. Individuals currently implanted with an electrical and/or neurostimulator device, such
             as cardiac pacemaker or defibrillator, vagal neurostimulator, deep brain stimulator,
             spinal stimulator, bone growth stimulator, or cochlear implant

         15. Known respiratory disease that has decreased any pulmonary function test more than 25%
             below expected values or has resulted in hospitalization within the past year

         16. All diagnosed syndromes affecting the central nervous system (CNS) or autonomic
             nervous system

         17. Major psychiatric disorders including evidence of major depressive disorder (DSM-5
             diagnostic criteria) that is not currently controlled by medications

         18. Hemoglobin below 9.0 gm/dL (by the most recent CBC)

         19. Pregnancy or breast feeding

         20. Inability or unwillingness to understand and/or sign informed consent

         21. Any other medical condition, whether or not related to lupus, which, in the opinion of
             the investigator, would render the patient inappropriate or too unstable to complete
             the study protocol
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Aikaterini Thanou, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Oklahoma Medical Research Foundation</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Oklahoma Medical Research Foundation</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>March 28, 2016</study_first_submitted>
  <study_first_submitted_qc>September 26, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 28, 2016</study_first_posted>
  <results_first_submitted>February 16, 2019</results_first_submitted>
  <results_first_submitted_qc>September 16, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">October 10, 2019</results_first_posted>
  <disposition_first_submitted>December 7, 2018</disposition_first_submitted>
  <disposition_first_submitted_qc>December 26, 2018</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">December 28, 2018</disposition_first_posted>
  <last_update_submitted>February 21, 2020</last_update_submitted>
  <last_update_submitted_qc>February 21, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 3, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Oklahoma Medical Research Foundation</investigator_affiliation>
    <investigator_full_name>Aikaterini Thanou</investigator_full_name>
    <investigator_title>Research Affiliate</investigator_title>
  </responsible_party>
  <keyword>vagus nerve stimulation</keyword>
  <keyword>systemic lupus erythematosus</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lupus Erythematosus, Systemic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>July 29, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/65/NCT02917265/Prot_SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants were recruited at the Rheumatology Research Clinic of the Oklahoma Medical Research Foundation between 9.2015 and 5.2017.</recruitment_details>
      <pre_assignment_details>Screening and randomization occurred at the same visit. One individual failed screening due to severe depression.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>TENS for Vagus Stimulation</title>
          <description>A transcutaneous electrical nerve stimulation (TENS) unit is applied to tragus, the area of the external ear innervated by the auricular branch of the vagus nerve.
TENS for vagus stimulation: TENS electrodes are applied the tragus of the external ear.</description>
        </group>
        <group group_id="P2">
          <title>TENS for Sham Stimulation</title>
          <description>A TENS unit is applied to the earlobe, an area of the external ear that is devoid of vagus innervation.
TENS for sham stimulation: TENS electrodes are applied on the earlobe.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>TENS for Vagus Stimulation</title>
          <description>A transcutaneous electrical nerve stimulation (TENS) unit is applied to an area of the external ear that is innervated by the auricular branch of the vagus nerve.
TENS for vagus stimulation: TENS electrodes are applied on an area of the external ear innervated by the auricular branch of the vagus nerve.</description>
        </group>
        <group group_id="B2">
          <title>TENS for Sham Stimulation</title>
          <description>A TENS unit is applied to an area of the external ear that is devoid of vagus innervation.
TENS for sham stimulation: TENS electrodes are applied on an area of the external ear devoid of vagus innervation.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="5"/>
            <count group_id="B2" value="2"/>
            <count group_id="B3" value="7"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50" lower_limit="25" upper_limit="69"/>
                    <measurement group_id="B2" value="51.5" lower_limit="43" upper_limit="60"/>
                    <measurement group_id="B3" value="50.4" lower_limit="25" upper_limit="69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Systemic Lupus Erythematosus Disease Activity Index (SLEDAI)</title>
          <description>The SLEDAI is the sum score of 24 variables to assess global lupus disease activity in the preceding 30 days. Scores can range from zero (no disease activity) to 105 (very active systemic lupus).
Disease activity categories: no activity: SLEDAI = 0, mild disease activity: SLEDAI = 1–5, moderate disease activity: SLEDAI = 6–10, high disease activity: SLEDAI = 11–19, very high disease activity: SLEDAI &gt;20</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4.6" lower_limit="4" upper_limit="6"/>
                    <measurement group_id="B2" value="4" lower_limit="2" upper_limit="6"/>
                    <measurement group_id="B3" value="4.4" lower_limit="2" upper_limit="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants on Active vs Sham tVNS With Improvement in SLE Disease Activity by the BILAG-based Combined Lupus Assessment (BICLA)</title>
        <description>Achieving a BICLA response requires to meet all of the following parameters:
All British Isles Lupus Assessment Group (BILAG) A scores improving to B/C/D and all BILAG level B scores improving to C/D
No single new BILAG A &amp; not &gt;1 new BILAG B scores, no worsening of the baseline Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) total score AND no worsening in the Physician Global Assessment (PGA) (&lt;10% worsening from baseline)
No initiation of non-protocol treatments or premature study discontinuation
The range of values for the above instruments are listed below, with higher scores indicating more active disease:
BILAG: 0 to 96 SLEDAI: 0 to 105 PGA: 0-3</description>
        <time_frame>12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>TENS for Vagus Stimulation</title>
            <description>A transcutaneous electrical nerve stimulation (TENS) unit is applied to tragus, the area of the external ear innervated by the auricular branch of the vagus nerve.
TENS for vagus stimulation: TENS electrodes are applied the tragus of the external ear.</description>
          </group>
          <group group_id="O2">
            <title>TENS for Sham Stimulation</title>
            <description>A TENS unit is applied to the earlobe, an area of the external ear that is devoid of vagus innervation.
TENS for sham stimulation: TENS electrodes are applied on the earlobe.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants on Active vs Sham tVNS With Improvement in SLE Disease Activity by the BILAG-based Combined Lupus Assessment (BICLA)</title>
          <description>Achieving a BICLA response requires to meet all of the following parameters:
All British Isles Lupus Assessment Group (BILAG) A scores improving to B/C/D and all BILAG level B scores improving to C/D
No single new BILAG A &amp; not &gt;1 new BILAG B scores, no worsening of the baseline Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) total score AND no worsening in the Physician Global Assessment (PGA) (&lt;10% worsening from baseline)
No initiation of non-protocol treatments or premature study discontinuation
The range of values for the above instruments are listed below, with higher scores indicating more active disease:
BILAG: 0 to 96 SLEDAI: 0 to 105 PGA: 0-3</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>BICLA responders</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BICLA non responders</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.05</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants on Active vs Sham tVNS With Improvement in SLE Disease Activity by the Systemic Lupus Erythematosus Responder Index (SRI-4)</title>
        <description>SRI requires meeting all of the following parameters:
≥4-point reduction from baseline in the Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) score
No single new British Isles Lupus Assessment Group (BILAG) A score &amp; not &gt;1 new BILAG B scores AND no worsening in the Physician Global Assessment (PGA) (&lt;10% worsening from baseline)
No initiation of non-protocol treatments or premature study discontinuation
The range of values for the above instruments are listed below, with higher scores indicating more active disease:
BILAG: 0 to 96 SLEDAI: 0 to 108 PGA: 0-3</description>
        <time_frame>12 weeks</time_frame>
        <population>all patients randomized to active treatment or placebo that had a total SLEDAI score of at least 4 at baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>TENS for Vagus Stimulation</title>
            <description>A transcutaneous electrical nerve stimulation (TENS) unit is applied to tragus, the area of the external ear innervated by the auricular branch of the vagus nerve.
TENS for vagus stimulation: TENS electrodes are applied the tragus of the external ear.</description>
          </group>
          <group group_id="O2">
            <title>TENS for Sham Stimulation</title>
            <description>A TENS unit is applied to the earlobe, an area of the external ear that is devoid of vagus innervation.
TENS for sham stimulation: TENS electrodes are applied on the earlobe.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants on Active vs Sham tVNS With Improvement in SLE Disease Activity by the Systemic Lupus Erythematosus Responder Index (SRI-4)</title>
          <description>SRI requires meeting all of the following parameters:
≥4-point reduction from baseline in the Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) score
No single new British Isles Lupus Assessment Group (BILAG) A score &amp; not &gt;1 new BILAG B scores AND no worsening in the Physician Global Assessment (PGA) (&lt;10% worsening from baseline)
No initiation of non-protocol treatments or premature study discontinuation
The range of values for the above instruments are listed below, with higher scores indicating more active disease:
BILAG: 0 to 96 SLEDAI: 0 to 108 PGA: 0-3</description>
          <population>all patients randomized to active treatment or placebo that had a total SLEDAI score of at least 4 at baseline.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>SRI Responders</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>SRI Non-responders</title>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants on Active vs Sham tVNS With Improvement in Heart Rate Variability (HRV)</title>
        <description>HRV is measured by time domain (RMSSD and pNN50) and frequency domain [high frequency (HF), low to high frequency (LF/HF) ratio] parameters.</description>
        <time_frame>12 weeks</time_frame>
        <population>Analysis not done.</population>
        <group_list>
          <group group_id="O1">
            <title>TENS for Vagus Stimulation</title>
            <description>A transcutaneous electrical nerve stimulation (TENS) unit is applied to tragus, the area of the external ear innervated by the auricular branch of the vagus nerve.
TENS for vagus stimulation: TENS electrodes are applied the tragus of the external ear.</description>
          </group>
          <group group_id="O2">
            <title>TENS for Sham Stimulation</title>
            <description>A TENS unit is applied to the earlobe, an area of the external ear that is devoid of vagus innervation.
TENS for sham stimulation: TENS electrodes are applied on the earlobe.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants on Active vs Sham tVNS With Improvement in Heart Rate Variability (HRV)</title>
          <description>HRV is measured by time domain (RMSSD and pNN50) and frequency domain [high frequency (HF), low to high frequency (LF/HF) ratio] parameters.</description>
          <population>Analysis not done.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Percentage of Participants on Active vs Sham tVNS That Experience an SLE Flare by SELENA SLEDAI Flare Index</title>
        <description>The SELENA SLEDAI flare index captures flares in the preceding 30 days by a combination of clinical descriptors and medications rules.</description>
        <time_frame>12 weeks</time_frame>
        <population>Analysis has not been done.</population>
        <group_list>
          <group group_id="O1">
            <title>TENS for Vagus Stimulation</title>
            <description>A transcutaneous electrical nerve stimulation (TENS) unit is applied to tragus, the area of the external ear innervated by the auricular branch of the vagus nerve.
TENS for vagus stimulation: TENS electrodes are applied the tragus of the external ear.</description>
          </group>
          <group group_id="O2">
            <title>TENS for Sham Stimulation</title>
            <description>A TENS unit is applied to the earlobe, an area of the external ear that is devoid of vagus innervation.
TENS for sham stimulation: TENS electrodes are applied on the earlobe.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants on Active vs Sham tVNS That Experience an SLE Flare by SELENA SLEDAI Flare Index</title>
          <description>The SELENA SLEDAI flare index captures flares in the preceding 30 days by a combination of clinical descriptors and medications rules.</description>
          <population>Analysis has not been done.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Percentage of Participants on Active vs Sham tVNS With Improvement in Quality of Life Measured by the Lupus QoL</title>
        <description>The Lupus QoL is a patient reported outcome developed for measurement of quality of life of patients with SLE in clinical research</description>
        <time_frame>12 weeks</time_frame>
        <population>Analysis not done.</population>
        <group_list>
          <group group_id="O1">
            <title>TENS for Vagus Stimulation</title>
            <description>A transcutaneous electrical nerve stimulation (TENS) unit is applied to an area of the external ear that is innervated by the auricular branch of the vagus nerve.
TENS for vagus stimulation: TENS electrodes are applied on an area of the external ear innervated by the auricular branch of the vagus nerve.</description>
          </group>
          <group group_id="O2">
            <title>TENS for Sham Stimulation</title>
            <description>A TENS unit is applied to an area of the external ear that is devoid of vagus innervation.
TENS for sham stimulation: TENS electrodes are applied on an area of the external ear devoid of vagus innervation.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants on Active vs Sham tVNS With Improvement in Quality of Life Measured by the Lupus QoL</title>
          <description>The Lupus QoL is a patient reported outcome developed for measurement of quality of life of patients with SLE in clinical research</description>
          <population>Analysis not done.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>12 weeks (baseline to Month 3)</time_frame>
      <group_list>
        <group group_id="E1">
          <title>TENS for Vagus Stimulation</title>
          <description>A transcutaneous electrical nerve stimulation (TENS) unit is applied to tragus, the area of the external ear innervated by the auricular branch of the vagus nerve.
TENS for vagus stimulation: TENS electrodes are applied the tragus of the external ear.</description>
        </group>
        <group group_id="E2">
          <title>TENS for Sham Stimulation</title>
          <description>A TENS unit is applied to the earlobe, an area of the external ear that is devoid of vagus innervation.
TENS for sham stimulation: TENS electrodes are applied on the earlobe.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>nausea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>paresthesias</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>carpal tunnel syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Urinary tract infections</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>cough</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Aikaterini Thanou, MD</name_or_title>
      <organization>Oklahoma Medical Research Foundation</organization>
      <phone>405-271-7805</phone>
      <email>aikaterini-thanou@omrf.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

